New biomarkers for response to immunotherapy
Update: 2017-07-28
Description
Prof Ribas speaks with ecancer at WIN 2017 about "the canary in the mine" of PDL-1 expression on tumour cells, and their response to checkpoint therapy.
He notes the off-target toxicities of ipilimumab, and the rationale for combining therapies to increase T cell infiltration beyond CTLA-4.
Prof Ribas notes the importance of the tumour microbiome in determining immunotherapy response, and the differing outcomes of adjuvant vs neoadjuvant staging.
He notes the off-target toxicities of ipilimumab, and the rationale for combining therapies to increase T cell infiltration beyond CTLA-4.
Prof Ribas notes the importance of the tumour microbiome in determining immunotherapy response, and the differing outcomes of adjuvant vs neoadjuvant staging.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
